Key lawmakers pressure Biden to preserve telehealth prescribing of effective addiction treatment

Key federal lawmakers are pressuring the Drug Enforcement Administration to preserve health providers’ ability to prescribe a highly effective opioid addiction treatment via telehealth.

In a letter delivered to the Biden administration on Wednesday, a bipartisan group led by Rep. Annie Kuster (D-N.H.) urged the DEA to continue allowing health providers to prescribe buprenorphine, a controlled substance used to treat opioid addiction, without requiring an in-person visit.

Prior to the Covid-19 pandemic, any patient who needed a controlled substance was required to be examined in person before receiving a prescription. But in early 2020, the DEA issued an emergency waiver that allowed health providers to prescribe the medications remotely. That waiver is set to expire at the end of 2024.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Supreme Court declines to review patent battle over inhalation powder Yutrepia

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 8, 2024

Nurses, Resident Slashed; Deadly Tick Disease Outbreak; COVID Vax After Infection

Note that some links may require registration or subscription Two nurses and one medical resident at Newark Beth Israel Medical Center were slashed by a

December 12, 2023

Cybin’s Leap Forward: DMT-Based Therapy Ready for Phase 2 Trials

The TDR Three Key Takeaways Innovative DMT-Based Therapies: Cybin Inc. is evolving psychedelic therapy with CYB004 and SPL028, derived from DMT. These therapies are significant

January 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.